Novartis Targets Ten Indications For Cosentyx
Potentially As Many As Humira
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.